Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336453 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
A Phase 1 study of Influenza, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
- 3
- Study locations
NCT00336453 is a Phase 1 study of Influenza that has completed, run by Protein Sciences Corporation. The registered enrollment target is 156 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00336453, a Phase 1 study of Influenza, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to 59 months.
Conditions Studied
Interventions
- BIOLOGICAL Influenza Vaccination
Study Locations (3)
Kentucky
- Kentucky pediatric /Adult Research - Bardstown
Missouri
- Saint Louis University - St Louis
Pennsylvania
- Primary Physicians Research - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336453
The ClinicalTrials.gov registry entry for NCT00336453 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Influenza Vaccination is the first listed.
NCT00336453 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kentucky, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00336453 about?
NCT00336453 is a clinical study titled "Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics". The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to 59 months.
What is the current status of trial NCT00336453?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2006-10. Estimated completion is 2007-07.
What conditions does trial NCT00336453 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00336453?
The interventions under investigation include: Influenza Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT00336453?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00336453 being conducted?
This trial has 3 study locations across Kentucky, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.